Distinction of endothelial cell growth and fibrinolytic activity between WKY/Izm and SHRSP/Izm in vitro.

Clinical and experimental pharmacology & physiology. Supplement Pub Date : 1995-12-01 DOI:10.1111/j.1440-1681.1995.tb02913.x

S Ito, Y Nara, Y Yamori

{"title":"Distinction of endothelial cell growth and fibrinolytic activity between WKY/Izm and SHRSP/Izm in vitro.","authors":"S Ito, Y Nara, Y Yamori","doi":"10.1111/j.1440-1681.1995.tb02913.x","DOIUrl":null,"url":null,"abstract":"<p><p>1. In the present study, endothelial cells (EC) growth and fibrinolytic activity of WKY/Izm and SHRSP/Izm were investigated in vitro. 2. EC were isolated from the thoracic aortas of WKY and SHRSP at the age of 8-9 weeks. Proliferative activities of EC were analysed with doubling time and DNA synthesis. Fibrinolytic activity was determined by tissue type plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) activities in cultured medium. 3. SHRSP-EC growth rate was significantly greater than WKY-EC growth rate in doubling time. In the assay for DNA synthesis, 5-bromo-2'-deoxy uridine incorporation rate in SHRSP-EC was significantly increased compared with that in WKY-EC. 4. The tPA activity in cultured medium of WKY-EC was 2-fold greater than that of SHRSP-EC, while PAI-1 activities were nearly equal in them. 5. These physiological distinctions of EC of SHRSP/Izm from that of WKY/Izm with close genetic background could be contributory genetic factors to hypertension-related vascular diseases in SHRSP.</p>","PeriodicalId":75710,"journal":{"name":"Clinical and experimental pharmacology & physiology. Supplement","volume":"22 1","pages":"S273-4"},"PeriodicalIF":0.0000,"publicationDate":"1995-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1681.1995.tb02913.x","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental pharmacology & physiology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/j.1440-1681.1995.tb02913.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

1. In the present study, endothelial cells (EC) growth and fibrinolytic activity of WKY/Izm and SHRSP/Izm were investigated in vitro. 2. EC were isolated from the thoracic aortas of WKY and SHRSP at the age of 8-9 weeks. Proliferative activities of EC were analysed with doubling time and DNA synthesis. Fibrinolytic activity was determined by tissue type plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) activities in cultured medium. 3. SHRSP-EC growth rate was significantly greater than WKY-EC growth rate in doubling time. In the assay for DNA synthesis, 5-bromo-2'-deoxy uridine incorporation rate in SHRSP-EC was significantly increased compared with that in WKY-EC. 4. The tPA activity in cultured medium of WKY-EC was 2-fold greater than that of SHRSP-EC, while PAI-1 activities were nearly equal in them. 5. These physiological distinctions of EC of SHRSP/Izm from that of WKY/Izm with close genetic background could be contributory genetic factors to hypertension-related vascular diseases in SHRSP.

查看原文本刊更多论文

WKY/Izm与SHRSP/Izm体外内皮细胞生长及纤溶活性的差异

1. 本研究在体外研究了WKY/Izm和SHRSP/Izm的内皮细胞(EC)生长和纤溶活性。2. 在8-9周龄时从WKY和SHRSP的胸主动脉中分离出EC。用倍增时间和DNA合成分析了EC的增殖活性。采用组织型纤溶酶原激活物(tPA)和1型纤溶酶原激活物抑制剂(PAI-1)活性测定培养基中纤溶酶活性。3.在倍增时间内，SHRSP-EC的生长速率显著大于WKY-EC的生长速率。在DNA合成实验中，与WKY-EC相比，SHRSP-EC的5-溴-2′-脱氧尿苷掺入率显著增加。4. WKY-EC培养基中tPA活性比SHRSP-EC高2倍，而PAI-1活性在两者中几乎相等。5. SHRSP/Izm与遗传背景相近的WKY/Izm的EC生理差异可能是SHRSP高血压相关血管疾病的重要遗传因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental pharmacology & physiology. Supplement

自引率

0.00%

发文量